ReviewCurrent treatment options in oncology2007
Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.
Review in Current treatment options in oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 77 citations in OpenAlex.
- BCL11B predetermines a persister state in breast cancer that is reversed by TNFα.Science advances · 2026Article
- A Percutaneous, High-Flow, Hyperthermic Isolated Limb Perfusion Technique for Extremity Malignancies: Point of Technique.Journal of surgical oncology · 2026Article
- TNF-alpha: Roles in pathogenesis and therapeutics in cancer.The Journal of biological chemistry · 2026Review
- Aging modulation of the immune system and immunotherapy efficacy in cancer.Frontiers in immunology · 2026Review
- Anaesthesia for isolated limb perfusion.BJA education · 2025Review
- Cytokines in cancer.Cancer cell · 2025Review
- Multifunctional gold nanoparticles for cancer theranostics.3 Biotech · 2024Review
- Effects of Nanosecond Pulsed Electric Field on Immune Checkpoint Receptors in Melanoma Cells.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Article
- Editorial: TNFRSF agonists: mode of action and therapeutic opportunities.Frontiers in immunology · 2023Article
- Blockade of innate inflammatory cytokines TNFImmunotherapy advances · 2023Article
- Isolated Limb Perfusion of Upper Limb: How I Do It.Indian journal of surgical oncology · 2022Article
- Tumor Necrosis Factor: What Is in a Name?Cancers · 2022Review
- Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience.Pharmaceutics · 2022Review
- Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.Clinical pharmacokinetics · 2022Article
- Tumor Necrosis Factor α: Taking a Personalized Road in Cancer Therapy.Frontiers in immunology · 2022Article
- Article
- Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance.Frontiers in physiology · 2021Review
- Prospects for NK Cell Therapy of Sarcoma.Cancers · 2020Review
- Gold Nanoparticles as a Potent Radiosensitizer: A Transdisciplinary Approach from Physics to Patient.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isolated limb perfusion (ILP) with chemotherapy alone has uniformly failed in the treatment of irresectable extremity soft tissue sarcomas. The addition of tumor necrosis factor-alpha (TNF-alpha) to this treatment approach contributed to a major step forward in the treatment of locally advanced extremity soft tissue sarcoma (STS). High response rates and limb salvage rates have been reported in multicenter trials, which combined ILP with TNF-alpha plus melphalan, which resulted in the approval of TNF-alpha for this indication in Europe in 1998. Subsequently a series of confirmatory single institution reports on the efficacy of the procedure have now been published. TNF-alpha has an early and a late effect; it enhances tumor-selective drug uptake during the perfusion and plays an essential role in the subsequent selective destruction of the tumor vasculature. These effects result in a high response rate in high-grade soft tissue sarcomas. This induction therapy thus allows for resection of tumor remnants some 3 months after ILP and thus avoidance of limb amputation. TNF-alpha-based ILP is a well-established treatment to avoid amputations. It represents an important example of tumor vascularity-modulating combination therapy and should be offered in large volume tertiary referral centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.